“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A study of ofatumumab with CHOP chemotherapy for Richter's syndrome (CHOP-OR)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
More about this trial
A combination of chemotherapy drugs called CHOP is the usual treatment for Richter’s syndrome. You might also have a drug called rituximab. This treatment can help to improve symptoms, but the lymphoma often comes back.
People who took part in this study had ofatumumab with CHOP chemotherapy to get rid of the lymphoma. This is called induction treatment. They then had more ofatumumab on its own to try and stop the lymphoma coming back. This is called maintenance treatment.
The aims of the trial were to:
- see if CHOP chemotherapy and ofatumumab helped people with Richter’s syndrome
- learn more about the side effects
Summary of results
The study team found that adding ofatumumab to CHOP didn’t improve the treatment outcomes for people with Richter’s syndrome.
This was a phase 2 study. Of the 43 people who took part, the team were able to look at the results of 37.
The researchers looked at how well CHOP with ofatumumab had worked for Richter’s syndrome. They found that for:
- 10 of the 37 people (27%) there was no sign of Richter’s syndrome (
- 7 out of 37 people (19%) their Richter’s syndrome had reduced (
When they looked at the average length of people were free of Richter’s syndrome after treatment it was just over 6 months.
The average length of time people lived after treatment was just under 11 ½ months.
The most severe side effects reported were:
- a drop in blood cells
- feeling or being sick
- high temperature (fever)
- skin reactions
The study team concluded that adding ofatumumab to CHOP and giving it as maintenance treatment didn’t work better than rituximab to control Richter’s syndrome.
But the team found that they could use CHOP with rituximab as the best treatment (
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Anna Schuh
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University of Oxford
This is Cancer Research UK trial number CRUKE/09/038.